Seer

Seer's Proteograph platform uses a panel of proprietary engineered nanoparticles to partition the proteome into reproducible subsets before mass spectrometry analysis. This sample-preparation step dramatically increases the number of proteins detected in a plasma sample — often thousands more than standard workflows — without requiring labs to buy new mass spectrometers. The result is deeper, more quantitative proteomic data from existing MS infrastructure.

Seer operates a razor-and-blade model. Customers purchase the Proteograph instrument and then buy consumable assay kits and nanoparticles on a recurring basis. The company also sells software analytics for proteomic data interpretation. Revenue is almost entirely product-driven, with a small services component for assay customization.

Seer was founded by Dr. Omid Farokhzad, a nanomedicine researcher who served on the faculty of Harvard Medical School and worked at Brigham and Women's Hospital. Milan Mrksich, a professor at Northwestern University and a leading bioengineer, is also a scientific co-founder. Farokhzad previously co-founded BIND Therapeutics and Selecta Biosciences, both clinical-stage biotech companies.

No. Seer is a life sciences tools company that sells instrumentation and consumables for proteomic discovery research. It has not commercialized any clinical diagnostic tests and does not hold FDA-cleared assays. Its customers are pharmaceutical companies and academic research labs that use the Proteograph to identify novel biomarkers and drug targets.

Seer serves the early discovery and translational research stages — before a drug candidate enters clinical trials. Its platform is used for unbiased biomarker discovery, patient stratification research, and target identification. The company does not participate in clinical trial services or regulated diagnostic development.

Indirectly. Seer does not manufacture mass spectrometers. Instead, its Proteograph system prepares samples for any high-resolution mass spectrometer. This positions Seer upstream of MS hardware vendors — existing Thermo, Bruker, or SCIEX instruments can produce richer datasets when paired with Seer's sample-prep technology, making it more of an add-on than a direct competitor.

Seer maintains an R&D center in Ra'anana, Israel, a location with deep talent in analytical instrumentation and mass spectrometry software. This office is focused on engineering and assay development, complementing the commercial and scientific operations in Redwood City and Billerica.